Glucoros (Fludeoxyglucose (18f))

Glucoros is employed in several PET imaging applications to visualize cellular glucose metabolism. It assists clinicians in diagnosing and managing a range of conditions.

• Oncologic PET imaging for tumor detection, staging, and therapy monitoring
• Cardiac PET imaging to evaluate myocardial viability and perfusion
• Neurologic PET imaging for epilepsy, dementia, and brain metabolism assessment
• Research studies investigating metabolic pathways in vivo
• Companion diagnostic for targeted therapies where metabolic activity guides treatment decisions

Side effects of Glucoros are generally related to its pharmacologic class and the radiation exposure associated with PET imaging.

Common

• Transient flushing or warmth sensation at the injection site
• Mild nausea or vomiting
• Temporary headache
• Short‑lasting dizziness or light‑headedness
• Mild allergic skin reactions such as erythema or itching

Serious

• Severe allergic reaction (anaphylaxis) with respiratory distress
• Significant radiation‑induced tissue injury (rare, dose‑related)
• Acute renal impairment in patients with pre‑existing kidney disease
• Cardiovascular events in high‑risk patients during imaging stress
• Persistent neurological symptoms following brain PET procedures

Glucoros should be used with careful consideration of patient‑specific factors and radiation safety guidelines.

• Assess pregnancy status; avoid use in pregnant women unless the diagnostic benefit outweighs potential fetal radiation risk
• Breastfeeding mothers should discontinue nursing for an appropriate period after administration
• Evaluate renal function, as impaired clearance may increase radiation exposure
• Screen for known hypersensitivity to fluorine‑18 labeled compounds
• Ensure proper hydration before and after injection to facilitate renal excretion
• Follow institutional radiation protection protocols for staff and environment

Glucoros may interact with substances that influence glucose metabolism or alter radiation distribution.

Avoid

• High‑dose glucose or dextrose infusions immediately before imaging, which can reduce tracer uptake
• Medications that significantly alter blood glucose levels (e.g., high‑dose insulin) without appropriate timing adjustments

Use with caution

• Antidiabetic agents (insulin, sulfonylureas) that may affect tracer distribution
• Beta‑blockers or calcium channel blockers that influence myocardial perfusion studies
• Contrast agents used in CT‑PET hybrid procedures, which may affect image interpretation
• Drugs that affect renal function, potentially altering tracer clearance